Aldeyra The
$ 5.46
-0.73%
27 Feb - close price
- Market Cap 328,489,000 USD
- Current Price $ 5.46
- High / Low $ 5.50 / 5.30
- Stock P/E N/A
- Book Value 0.82
- EPS -0.73
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -0.64 %
- 52 Week High 7.20
- 52 Week Low 1.14
About
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.
Analyst Target Price
$9.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-07 | 2025-04-30 | 2025-03-05 | 2024-11-01 | 2024-08-01 | 2024-05-02 | 2024-03-07 | 2023-11-03 | 2023-08-03 | 2023-05-04 | 2023-03-09 |
| Reported EPS | -0.13 | -0.16 | -0.17 | -0.27 | -0.25 | -0.28 | -0.14 | -0.08 | -0.14 | -0.15 | -0.27 | -0.22 |
| Estimated EPS | -0.245 | -0.2433 | -0.244 | -0.2173 | -0.25 | -0.14 | -0.11 | -0.14 | -0.24 | -0.31 | -0.29 | -0.31 |
| Surprise | 0.115 | 0.0833 | 0.074 | -0.0527 | 0 | -0.14 | -0.03 | 0.06 | 0.1 | 0.16 | 0.02 | 0.09 |
| Surprise Percentage | 46.9388% | 34.2376% | 30.3279% | -24.2522% | 0% | -100% | -27.2727% | 42.8571% | 41.6667% | 51.6129% | 6.8966% | 29.0323% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.155 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALDX
2026-02-27 21:53:03
Aldeyra Therapeutics, Inc. has released its annual 10-K report, detailing a net loss of $33.8 million, a significant decrease from the previous year, primarily due to reduced R&D and G&A expenses. The company is advancing a robust product pipeline, including reproxalap and ADX-2191, and has an exclusive option agreement with AbbVie. Despite regulatory challenges with reproxalap, Aldeyra plans to initiate clinical trials for new RASP modulators and continue seeking additional capital for future development and commercialization.
2026-02-20 09:53:13
Aldeyra Therapeutics (NASDAQ:ALDX) stock saw its price fall below its 200-day moving average to $5.02, trading as low as $4.91 on Wednesday. Despite this technical breach, the company retains a "Hold" consensus rating with a $9.50 price target from analysts, indicating potential upside. Institutional investors hold nearly 60% of shares, and Aldeyra, a clinical-stage biopharma, focuses on developing treatments for ophthalmic inflammatory disorders.
2026-02-20 06:38:00
Aldeyra Therapeutics Inc. (ALDX) is currently facing weak near and mid-term sentiment despite a strong long-term outlook, with support levels being tested. Institutional trading strategies identify a significant risk-reward setup targeting a 29.2% gain if the $5.30 support holds, while multi-timeframe analysis highlights key resistance at $6.85.
2026-02-20 03:12:12
Aldeyra Therapeutics (ALDX) shares have seen a 0.6% gain recently, with Wall Street analysts projecting a potential upside of 79.3%, reaching a mean estimate of $9.00. While price targets can be misleading, the strong agreement among analysts and a 19.4% increase in the Zacks Consensus Estimate for current year earnings suggest a legitimate reason for optimism. ALDX currently holds a Zacks Rank #2 (Buy), indicating further potential upside in the near term.
2026-02-19 16:57:06
Aldeyra Therapeutics (ALDX) shares have seen a recent gain, and Wall Street analysts project a potential upside of 79.3%, with a mean target of $9. This optimistic forecast is further supported by a strong consensus among analysts regarding higher earnings estimates, leading to a Zacks Rank #2 (Buy). While investors should be cautious with price targets, the agreement and improved earnings outlook suggest a positive short-term outlook for ALDX.
2026-02-18 23:18:59
Aldeyra Therapeutics, a biotechnology company, announced that its President and CEO, Todd C. Brady, M.D., Ph.D., will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. The event is scheduled for February 25, 2026, at 10:40 a.m. ET, where Dr. Brady will converse with Andreas Argyrides, Senior Biotech Analyst at Oppenheimer & Co. Inc. The webcast will be available on Aldeyra's investor relations website.
